Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic (NDM) disorders.
NaMuscla is the first licenced antimyotonic proven to:
• control symptoms of myotonia in adult patients with NDM.1,2
• improve patient’s daily lives.1,2
• provide generally well-tolerated, long-term myotonia relief.3
Myotonia is more than an inability to relax muscles.5
Myotonia is a chronic, lifelong condition that impacts NDM patients on a daily basis.5
Untreated myotonia can have dramatic consequences for NDM patients.1
Myotonia restricts everyday life.1
NaMuscla: 1st licensed antimyotonic proven to control symptomatic myotonia.1-2
Proven effective relief from NDM-related myotonia.1
Long-term relief from myotonia irrespective of channelopathy - a retrospective chart review.3
NaMuscla: Well tolerated, and suitable for long-term use.3
Long-term experience in patients with NDM – retropective chart review (4.5y).3
NaMuscla: A daily, long-term treatment for relief from myotonia.1
NaMuscla composition & dosing.1
Each patient should be given a Patient Alert card before initiating treatment with NaMuscla®
Healthcare Professional Education Guide and Patient Alert cards can be requested from: email@example.com
References: 1. Summary of Product Characteristics, NaMuscla® 167mg hard capsules, Lupin Europe GmbH 2018. 2. Statland JM, et al. JAMA 2012; 308:(13):1357-65. 3. Suetterlin KJ, et al. JAMA Neurology 2015; 72(12);1531-3. 4. Trivedi JR, et al. Brain 2013; 136:2189-2200. 5. Trip J, et al. J Neurol 2009; 256:939-47. 6. MyoPath (Myotonia Observational Survey of Patient Access to Therapy avoiding Harm) 2018, Lupin, Data on File.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the leaflet. You can also report side effects directly by the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
167mg Hard Capsules
|Product Licence Number||PL 35507/0191|
|Lupin Product Code||416225|
|Pack Size||30 Capsules|
Namuscla Supply Chain
At Lupin Healthcare we recognise the importance of continued supply of branded medicines and are committed to the highest quality standards. With this in mind we supply our products through all three major UK wholesalers.
LUP-CORP-005s DOP: October 2020
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.